BioSpace News Archive

Business

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

October 11, 2024
·
1 min read
News

Judo Bio to Present Data at the ASN Kidney Week 2024 Demonstrating Receptor‑mediated Delivery of Oligonucleotides to the Kidney

October 11, 2024
·
1 min read
IPO

Upstream Raises $255M IPO for Inflammatory Drugs; CAMP4 Nets $75M for RNA Work

Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease work, while CAMP4 Therapeutics picked up $75 million to develop RNA-targeting drugs.

October 11, 2024
·
1 min read
·
Annalee Armstrong
Layoffs

Turnstone Biologics to Lay Off 60% of Workforce, Overhaul C-Suite

Turnstone is shifting resources to focus on clinical advancement of its selected tumor-infiltrating lymphocyte therapy as three C-suite members exit their roles.

October 11, 2024
·
2 min read
·
Angela Gabriel
Editorial

Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.

October 11, 2024
·
3 min read
·
Greg Slabodkin
Business

Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024

October 11, 2024
·
1 min read
FDA

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

October 11, 2024
·
14 min read
FDA

FDA Approves New Treatment for Hemophilia A or B

October 11, 2024
·
3 min read
Business

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

October 11, 2024
·
14 min read